Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome ...Middle East

PARAMUS, N.J., Aug. 2, 2021 /PRNewswire/ -- Epygenix Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy announced today that the European Medicines Agency (EMA) granted Orphan Medicinal Product Designation to EPX-200 for the...

Read More Details
Finally We wish PressBee provided you with enough information of ( Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome )

Also on site :

• Chart-Topping '90s Rocker, 59, Stuns Fans With Unexpected Side Career
• Country Legend Makes Generous Donations Across North America This Summer
• 3 'Micro Workouts' That Take Less Time Than Brushing Your Teeth